Aurélie Thedrez

Aurélie Thedrez

Auto-generated profile, based on publicly available information

Aurélie Thedrez

L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2007 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
ATAurélie Thedrez
Aurélie Thedrez
CSCaroline Sabourin
Caroline Sabourin
JGJulie Gertner
Julie Gertner
MDMarie‐Claire Devilder
Marie‐Claire Devilder
SASophie Allain‐Maillet
Sophie Allain‐Maillet
MBMarc Bonneville
Marc Bonneville

1 October 2016 in JACC: Basic To Translational Science
Verified
Journal Article
Open access
EVElise F. Villard
Elise F. Villard
ATAurélie Thedrez
Aurélie Thedrez
JBJorg Blankenstein
Jorg Blankenstein
MCMikaël Croyal
Mikaël Croyal
TTThi-Thu-Trang Tran
Thi-Thu-Trang Tran
GLGilles Lambert
Gilles Lambert
• Unlike LDL uptake, Lp(a) uptake is not altered by PCSK9 or PCSK9 inhibition in primary human hepatocytes and in primary dermal fibroblasts isolated from familial hypercholesterolemic and non–familial hypercholesterolemic patients. • Lp(a) uptake is occurring in the absence of a functional LDL receptor and is not affected by LDL receptor blockade with monoclonal antibodies. • Lp(a) cellular binding and whole particle uptake are not altered by PCSK9. • The secretion of Lp(a) from primary human hepatocytes is enhanced by PCSK9, an effect that is blunted by PCSK9 inhibition with alirocumab.

1 March 2018 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
ATAurélie Thedrez
Aurélie Thedrez
DBDirk J. Blom
Dirk J. Blom
SRStéphane Ramin-Mangata
Stéphane Ramin-Mangata
VBValentin Georges Marcel Blanchard
Valentin Georges Marcel Blanchard
MCMikaël Croyal
Mikaël Croyal
GLGilles Lambert
Gilles Lambert
Objective—Evolocumab, a PCSK9 (proprotein convertase subtilisin kexin type 9)–neutralizing antibody, lowers low-density lipoprotein cholesterol (LDL-C) in homozygous familial hypercholesterolemic (HoFH) patients with reduced LDLR (low-density lipoprotein receptor) function. However, their individual responses are highly variable, even among carriers of identical LDLR genetic defects. We aimed to elucidate why HoFH patients variably respond to PCSK9 inhibition. Approach and Results—Lymphocytes were isolated from 22 HoFH patients enrolled in the TAUSSIG trial. Ten patients were true homozygotes (FH1/FH1) and 5 identical compound heterozygotes (FH1/FH2). Lymphocytes were plated with or without mevastatin, recombinant PCSK9 (rPCSK9), or a PCSK9-neutralizing antibody. Cell surface LDLR expression was analyzed by flow cytometry. All HoFH lymphocytes had reduced cell surface LDLR expression compared with non-FH lymphocytes, for each treatment modality. Lymphocytes from FH1/FH2 patients (LDLR defective/negative) displayed the lowest LDLR expression levels followed by lymphocytes from FH1/FH1 patients (defective/defective). Mevastatin increased, whereas rPCSK9 reduced LDLR expression. The PCSK9-neutralizing antibody restored LDLR expression. Lymphocytes displaying higher LDLR expression levels were those isolated from patients presenting with lowest levels of LDL-C and apolipoprotein B, before and after 24 weeks of evolocumab treatment. These negative correlations remained significant in FH1/FH1 patients and appeared more pronounced when patients with apolipoprotein E3/E3 genotypes were analyzed separately. Significant positive correlations were found between the levels of LDLR expression and the percentage reduction in LDL-C on evolocumab treatment. Conclusions—Residual LDLR expression in HoFH is a major determinant of LDL-C levels and seems to drive their individual response to evolocumab.

15 March 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ATAurélie Thedrez
Aurélie Thedrez
CHChristelle Harly
Christelle Harly
AMAlexis Morice
Alexis Morice
SSSamuel Salot
Samuel Salot
MBMarc Bonneville
Marc Bonneville
ESEmmanuel SCOTET
Emmanuel SCOTET
Vγ9Vδ2 T lymphocytes are a major human γδ T cell subset that react against a wide array of tumor cells, through recognition of phosphorylated isoprenoid pathway metabolites called phosphoantigens. Immunotherapeutic protocols targeting Vγ9Vδ2 T cells have yielded promising, yet limited, signs of antitumor efficacy. To improve these approaches, we analyzed the effects on γδ T cells of IL-21, a cytokine known to enhance proliferation and effector functions of CD8+ T cells and NK cells. IL-21 induced limited division of phosphoantigen-stimulated Vγ9Vδ2 T cells, but did not modulate their sustained expansion induced by exogenous IL-2. Vγ9Vδ2 T cells expanded in the presence of IL-21 and IL-2 showed enhanced antitumor cytolytic responses, associated with increased expression of CD56 and several lytic molecules, and increased tumor-induced degranulation capacity. IL-21 plus IL-2-expanded Vγ9Vδ2 T cells expressed higher levels of inhibitory receptors (e.g., ILT2 and NKG2A) and lower levels of the costimulatory molecule NKG2D. Importantly, these changes were rapidly and reversibly induced after short-term culture with IL-21. Finally, IL-21 irreversibly enhanced the proinflammatory Th1 polarization of expanded Vγ9Vδ2 T cells when added at the beginning of the culture. These data suggest a new role played by IL-21 in the cytotoxic and Th1 programming of precommitted Ag-stimulated γδ T cells. On a more applied standpoint, IL-21 could be combined to IL-2 to enhance γδ T cell-mediated antitumor responses, and thus represents a promising way to optimize immunotherapies targeting this cell subset.

1 November 2016 in Atherosclerosis
Verified
Journal Article
Closed access
RARodrigo Alonso
Rodrigo Alonso
PMPedro Mata
Pedro Mata
OMOvidio Muñiz
Ovidio Muñiz
FJFRANCISCO FUENTES JIMENEZ
FRANCISCO FUENTES JIMENEZ
JDJose Luis Díaz
Jose Luis Díaz
GLGilles Lambert
Gilles Lambert

13 June 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Vincent LavouéVincent Lavoué
Vincent Lavoué
ATAurélie Thédrez
Aurélie Thédrez
JLJean Levêque
Jean Levêque
FFFabrice Foucher
Fabrice Foucher
SHSébastien Henno
Sébastien Henno
FCFlorian Cabillic
Florian Cabillic
Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women, and there has been no substantial decrease in the death rates due to EOC in the last three decades. Thus, basic knowledge regarding ovarian tumor cell biology is urgently needed to allow the development of innovative treatments for EOC. Traditionally, EOC has not been considered an immunogenic tumor, but there is evidence of an immune response to EOC in patients. Clinical data demonstrate that an antitumor immune response and immune evasion mechanisms are correlated with a better and lower survival, respectively, providing evidence for the immunoediting hypothesis in EOC. This review focuses on the immune response and immune suppression in EOC. The immunological roles of chemotherapy and surgery in EOC are also described. Finally, we detail pilot data supporting the efficiency of immunotherapy in the treatment of EOC and the emerging concept that immunomodulation aimed at counteracting the immunosuppressive microenvironment must be associated with immunotherapy strategies.